SNOA Sonoma Pharmaceuticals (SNOA) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001367083
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
Sonoma Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Sonoma Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 95% of Medical Devices
Revenue
+36.7% year over year
more than 83% of Medical Devices
Margin
-16.3% net margin
more than 51% of Medical Devices
Buybacks
no share repurchases reported
Short interest
2.3% of the float short (float per yahoo 2026-10-27) · 2.8 days to cover · settled 2026-10-15
below 61% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SNOA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-69.6%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SNOA: institutional holders (13F)
13F holdings, latest reported quarter
40,468 sh
$49.8K
26,787 sh
$32.9K
18,787 sh
$23.1K
$13.8K
7,808 sh
$9.6K
Congress trades in SNOA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SNOA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SNOA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$15.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$23.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$2.6K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Amy Trombly
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$741.1K
$641.7K
$411.2K
-89%
n/a
2024
$597.1K
$553.9K
$444.9K
-89%
n/a
2023
$726.5K
$697.4K
$483.1K
-83%
n/a
2022
$559.9K
$509.8K
$299.2K
-76%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SNOA financials
Revenue growth
+36.7%
XBRL, annual
Net margin
-16.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SNOA
| FY Mar 2026 | $19.5M |
| FY Mar 2025 | $14.3M |
| FY Mar 2024 | $12.7M |
| FY Mar 2023 | $13.3M |
| FY Mar 2022 | $12.6M |
| Jun 2026 | $6.4M |
| Mar 2026 | $5.6M |
| Dec 2025 | $4.3M |
| Sep 2025 | $5.6M |
| Jun 2025 | $4.0M |
| Mar 2025 | $3.8M |
| Dec 2024 | $3.6M |
| Sep 2024 | $3.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+4.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SNOA
| FY Mar 2026 | +0.0% |
| FY Mar 2025 | +0.0% |
| FY Mar 2024 | +0.0% |
| FY Mar 2023 | -38.8% |
| FY Mar 2022 | -40.3% |
| Jun 2026 | -5.2% |
| Mar 2026 | +46.7% |
| Dec 2025 | -18.8% |
| Sep 2025 | -9.5% |
| Jun 2025 | -30.9% |
| Mar 2025 | +71.5% |
| Dec 2024 | -26.0% |
| Sep 2024 | -17.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$2.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SNOA
| FY Mar 2026 | -$4.1M |
| FY Mar 2025 | -$168.0K |
| FY Mar 2024 | -$2.4M |
| FY Mar 2023 | -$6.4M |
| FY Mar 2022 | -$4.4M |
| Jun 2026 | -$651.0K |
| Mar 2026 | -$548.0K |
| Dec 2025 | -$811.0K |
| Sep 2025 | -$645.0K |
| Jun 2025 | -$2.1M |
| Mar 2025 | -$142.0K |
| Dec 2024 | $563.0K |
| Sep 2024 | $328.0K |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2022-12-31 (42 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Debt to equity SNOA
| FY Mar 2026 | 0.08x |
| FY Mar 2025 | 0.05x |
| FY Mar 2024 | 0.06x |
| FY Mar 2023 | 0.06x |
| FY Mar 2022 | 0.07x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.08x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.04x |
| Mar 2025 | 0.05x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-16.56x
TTM operating cash flow over long-term 2022-12-31 (42 months older than the period end) plus current 2026-06-30
Cash flow to debt SNOA
| FY Mar 2026 | -16.59x |
| FY Mar 2025 | -0.37x |
| FY Mar 2024 | -7.09x |
| FY Mar 2023 | -13.79x |
| FY Mar 2022 | -7.13x |
| Jun 2026 | -16.56x |
| Mar 2026 | -16.59x |
| Dec 2025 | -233.93x |
| Sep 2025 | -30.70x |
| Jun 2025 | -7.73x |
| Mar 2025 | -0.37x |
| Dec 2024 | 10.60x |
| Sep 2024 | -15.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+17.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SNOA
| FY Mar 2026 | +0.1% |
| FY Mar 2025 | +0.1% |
| FY Mar 2024 | +0.1% |
| FY Mar 2023 | -61.8% |
| FY Mar 2022 | -72.3% |
| Jun 2026 | +17.2% |
| Mar 2026 | +0.1% |
| Dec 2025 | +2.2% |
| Sep 2025 | -0.4% |
| Jun 2025 | -2.1% |
| Mar 2025 | +0.1% |
| Dec 2024 | +18.9% |
| Sep 2024 | +20.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+5.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SNOA
| FY Mar 2026 | +0.0% |
| FY Mar 2025 | +0.0% |
| FY Mar 2024 | +0.0% |
| FY Mar 2023 | -29.4% |
| FY Mar 2022 | -30.1% |
| Jun 2026 | +5.6% |
| Mar 2026 | +0.0% |
| Dec 2025 | +0.7% |
| Sep 2025 | -0.1% |
| Jun 2025 | -0.7% |
| Mar 2025 | +0.0% |
| Dec 2024 | +7.7% |
| Sep 2024 | +8.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SNOA
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-12.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SNOA
| FY Mar 2026 | -26.3% |
| FY Mar 2025 | -36.0% |
| FY Mar 2024 | -39.9% |
| FY Mar 2023 | -35.8% |
| FY Mar 2022 | -49.2% |
| Jun 2026 | -12.6% |
| Mar 2026 | -26.3% |
| Dec 2025 | -28.6% |
| Sep 2025 | -31.3% |
| Jun 2025 | -36.9% |
| Mar 2025 | -36.0% |
| Dec 2024 | -41.5% |
| Sep 2024 | -41.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SNOA
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$180.0K
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term 2022-12-31 (42 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
Enterprise value SNOA
| FY Mar 2026 | $1.5M |
| FY Mar 2025 | -$1.6M |
| FY Mar 2024 | $50.3M |
| FY Mar 2023 | $87.8M |
| FY Mar 2022 | $241.6M |
| Jun 2026 | $703.5K |
| Mar 2026 | $1.5M |
| Dec 2025 | $3.6M |
| Sep 2025 | $3.4M |
| Jun 2025 | $1.2M |
| Mar 2025 | -$1.6M |
| Dec 2024 | -$1.6M |
| Sep 2024 | $54.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-49.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield SNOA
| FY Mar 2026 | -111.9% |
| FY Mar 2025 | -4.7% |
| FY Mar 2024 | -4.5% |
| FY Mar 2023 | -7.0% |
| FY Mar 2022 | -1.8% |
| Jun 2026 | -45.1% |
| Mar 2026 | -111.9% |
| Dec 2025 | -60.1% |
| Sep 2025 | -36.8% |
| Jun 2025 | -29.3% |
| Mar 2025 | -4.7% |
| Dec 2024 | +4.0% |
| Sep 2024 | -2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SNOA
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M |
| Operating income | -$2.5M | -$3.7M | -$4.7M | -$4.6M |
| Net income | $3.2K | $3.5K | $4.8K | -$5.2M |
| EPS (diluted) | n/a | n/a | n/a | -1.52 |
| Operating cash flow | -$3.9M | -$88.0K | -$2.4M | -$6.2M |
| Cash | $2.4M | $5.4M | $3.1M | $3.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
SNOA Stock Sonar score 5/7 axes
Find similar shapesCompareSNOA ranks highest on growth (83rd percentile) and risk and compliance (81st), and lowest on institutional and government (5th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
